I am a buy and hold common stock investor. Warren Buffett is definitely my guru. He makes the most sense to me. I began investing in the stock market at age 14 in 1970 with money earned on my paper route. What I have done since 1970 is invest primarily in the Dividend Aristocrats whenever the stock market is relatively low. I have never sold a single share of stock except on the rare occasion when one of my stocks was bought out for cash and I was forced to sell.. I keep all of my stock certificates or direct registration statements in a safe deposit box at the bank. I do not automatically reinvest dividends. I only purchase stocks when I feel that the stock market is relatively low. Brown University, B. A., 1978. Below are the 35 stocks in my portfolio.
Portfolio Management 101 is led by CFA Charterholders with combined investment experience of over 25 years. The articles written by PM101 are intended to be informative and may contain opinions on the soundness of particular investments but should not be considered a recommendation for any particular investor. For this reason, we attempt to not only outline the reasons why we think an investment looks attractive but also highlight the risks that the investment entails. Investors should consider their own investment objectives and profile before using any of PM101 articles as the basis for investment.
Suhail Capital Management is a Cayman Domiciled Private Investment Firm. We focus on event driven long/short opportunities in what we believe to be seriously mispriced global listed securities.
Surgeon with a highly varied background. Mixture of buy and hold equities and higher risk securities and LEAP calls.
The picture is James K. Polk; one of our most successful and underrated presidents. Ran for office stating he would accomplish 4 things. Accomplished all four, died shortly after his term completely exhausted.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Parker Logan Advisors is a Registered Investment Adviser providing investment management services in New York. We utilize Seeking Alpha to share our insights to the general investing public.
Own over 50 dividend paying stocks. Our holdings by sector. Animal Health/Dental: PDCO. Chemical/Agriculture: DOW, DD, FMC and MON. Consumer Defensive: KO, PG, MO, KMB, GIS, MDLZ, CLX, CL, KHC, HSY and SJM. Consumer Cyclical: SBUX, NKE and COH. Healthcare: ABT, ABBV, BMY,BAX, DGX, JNJ, LLY, PFE, MRK and HYH. Tech: ADP, ORCL, IBM, INTC, GLW, HPQ, HPE, NATI and TXN. Industrial: EMR, ITW, MMM, HON and GE. Financial: FITB. Telecom: T and VZ. Utility: AEP Miscellaneous: AVY, CDK, FAST, FBHS and SPGI.
I am an individual and occasional investor with a passion for biotechnology and stocks. I am working as an engineer with ties to the healthcare sector.
I build investment theses based on thorough personal research and end up picking only stocks that I think hold a very high and long-term potential. I specialize in micro-cap and/or European biotechs, tracking undervalued opportunities and basing my investment choices on the deep analysis of a company's fundamentals and its long-term perspective (at least several years).
Follow me on twitter: https://twitter.com/Logribel
The Clinically Sound Investor is a pharmacist for a large retail corporation, with a PharmD and a BA in psychology. Fascinated by watching the rise of Walmart and Apple after 2008, he now follows the advice "know thyself" and puts expertise of understaning scientific literature to research biotechnology stocks. His investments early on were driven by binary events such as FDA Advisory Committee meetings and PDUFA dates (approvals). Despite initial successes, there were too few of these events, so he expanded into predicting Phase II/III trial results.
His writings should not be considered financial advice or the basis for investment decisions. While his interpretations of clinical trial results--which may be overlooked or even thoroughly misunderstood by Wall Street--could be helpful, they're only as good as the original reports they come from. Although written by scientists and doctors, there will always be a slant from the sponsoring company, or worse (like, say, missing data...).
I have a B.S. in Economics from West Point and an MBA from Penn State. I have invested in stocks for over 15 years. And I have written articles on stocks for the past few years for various sites such as Motley Fool, CNN Money, MSN Money, and Yahoo Finance (to name a few). I have also published two books, which are sold in bookstores and on sites such as Amazon.com. I specialize in international equities and how geopolitics (international relations) impacts equities and markets. Furthermore, I enjoy leveraging my background in marketing (P&G), strategic planning (Lockheed Martin), consulting (Pinnacle Consulting) and as a former All-Source Intelligence Officer to analyze stocks through multiple lenses. I believe that the key is to find the small percentage of information that requires further analysis. I am willing to take calculated risks in order to achieve a higher expected return.
Founder of Old School Value (www.oldschoolvalue.com).
Fundamental Stock Analyzer & Valuation Tool for Value Investors to Save Time & Make Money
- Are you spending a lot of time manually gathering and inputting data into spreadsheets?
- Are you finding it difficult to keep up to date with fundamental company valuations?
- Do you need a way to quickly check whether a company is worth investigating?
- Do you want to know what a company is worth quickly?
The Old School Value Stock Analysis Software is a fundamental analysis and valuation tool that works for you.
Save hours each day by automatically retrieving and crunching the financials for thousands of companies.
Keep up to date easily and find more opportunities by analyzing companies faster and use the 5 valuation models to cross check whether the stock price is an attractive entry price or time to get out.
Learn more at http://try.oldschoolvalue.com/stock-analyzer/
Many year investor now into options still learning a great deal and trying to control my emotions. Like tech and biotech as well as some commodities. Like dividend players a lot ESP MLPs. And some Reits. Learning more and more about options for added leverage. Am a physician Therefore have a better understanding of biotech products and binary trades
I worked almost 30 years in the pharmaceutical industry. I started as a sales rep after earning my degree in biological sciences and (later) biomedical sciences. I then went back to school, got my MBA, and spent the following 20 years working up the ranks. I spent the latter parts of my career working as an analyst, meaning I would analyze data on 1,000s of compounds, collect reports from scientists, and then present the information to those who decided whether the candidates would go on to clinical trials (additional preclinical studies) or would be thrown to the dumpster for some small company to find and develop further. I have worked in just about every department in the pharmaceutical industry, including biotechnology, oncology, infectious disease, genetics, etc.
Now that I am recently retired, I have joined Seeking Alpha to share my knowledge of the healthcare industry, and discuss trends that I've seen throughout my career. I have chosen the task of managing my own retirement accounts, therefore Seeking Alpha has become a great interest to me.
I am hoping to learn and teach via Seeking Alpha. Also, my grandchildren call me Shennie so that's what I go by these days
I joined Seeking Alpha in February 2014 as editor of the biotech vertical. In addition to onboarding new contributors, my job is to make sure Seeking Alpha provides high-quality and comprehensive coverage of the biotechnology and health care sectors. I am always looking for new ideas, so please reach out if you're interested.
I'm a founder of finbox.io which offers a suite of fundamental investing tools that makes it easy to find undervalued stocks. Finbox.io has been featured in Barron’s Magazine on multiple occasions which can be viewed here: https://blog.finbox.io/barrons-features-finbox-io/. My goal is to help investors of all sizes make fundamentally sound investment decisions in the stock market. I previously worked as an investment banking associate advising business owners, boards of directors and management teams on a broad range of transactions.
A Canadian with numerous years of investment experience who has a BCom degree from a well respected Canadian university and has experience working in the wealth management industry.
Lowenthal Capital Partners is operated by Trevor Lowenthal. Trevor graduated with a BA in Political Science from University of California, Davis with Summa Cum Laude distinction. Trevor is finishing his J.D. at the University of Colorado Law School.
Asif Suria is an entrepreneur and investor with a focus on event driven strategies including merger arbitrage and insider trading. He publishes a weekly post that includes the latest mergers and highlights the largest spreads. He also publishes a weekly post that highlights the top 5 insider purchases and sales of the week.
Asif is also one of the earliest contributors at Seeking Alpha and has been regularly contributing content since 2005.
Professionally, I have done a bit of everything in my long life, from playing rock and roll, to developing software, and running a successful entrepreneurial business. But I am best known as a writer of bestselling books about business and health. I write under a pseudonym here on Seeking Alpha because that way I know readers will evaluate my work strictly on the basis of what I actually said rather than who I am.
Computer engineer retired in 2008 living off IRA savings mostly stocks. Maintain significant cash position to withstand drawdowns, which allowed me to hold on through the great recession. I also enjoy IPA's.
Rocco Pendola is an associate editor at Seeking Alpha focusing on technology and the sectors it overlaps with.
In addition to technology, I am interested in dividend growth and income investing.
I make references to music I'm obsessed with (e.g., Old 97s, Elliott Smith, Bruce Springsteen) in my writing. If you notice any of these references, it makes me happy.
The Jaded Consumer (pseudonym) has master's and doctorate degrees in fields related to health policy and policy analysis, and routinely assists small businesses operating in fields characterized by complex or uncertain regulation. TJC believes that an investment produces enduring returns when backed by compelling reasons that profitability and competitive position can be maintained over time in the face of competitors eager to succeed in the same markets. TJC views real-world markets as ordinary human institutions subject to common mistakes and fears, and is eager to invest in companies whose businesses appear to be widely misunderstood in ways that discount their apparent future performance.
I am an investor looking to find companies that are undervalued or are in the process of being influenced. As I learn about new companies, I write my articles as a way of forcing more in depth research. By writing, it requires me to ask more questions.
Educational background in economics/finance, MBA in finance.
Professional experience in corporate finance,project finance,securities.
Over 50 years of personal investing experience.
Retired. Investing for total return, to maintain my slovenly lifestyle.
I am a dog on Fate's vivisection table.